TO THE EDITOR
Acute promyelocytic leukemia (APL) is distinguished from other types of acute myeloid leukemia by particular morphologic features. Management and prognosis of APL is considerably different from other forms of acute myeloid leukemia (AML), which underlines the need for accurate diagnosis. 1, 2 Both forms, the hypergranular M3 and the hypogranular M3v, share the t(15;17) as cytogenetic characteristic. Establishment of t(15;17) or/and PML-RARa fusion gene is pivotal for optimal treatment of APL, since a favorable response to combination therapy with alltrans retinoic acid (ATRA) and chemotherapy is restricted to patients with these rearrangements. 3 Although t(15;17)(q22;q21) and PML-RARa gene fusion is recognized to be a typical defect of APL, it is now apparent that some cases with typical APL morphology show cryptic PML-RARa rearrangements not detectable by conventional cytogenetics. 4, 5 The 45-year-old female patient had been well 1 month before until vaginal and perianal bleeding appeared together with progressive weakness, fever up to 381C, night sweating, and headache. At admission, she presented with various hematomas and a moderate splenomegaly with 14 Â 5.6 cm in diameter. The blood counts showed anemia with hemoglobin at 9.7 g/dl, thrombocytopenia of 66 Â 10 3 /ml, leukocytosis of 13 Â 10 3 /ml, and a differential count containing 9% band neutrophils, 6% segmented neutrophils, 1% eosinophils, 22% lymphocytes, 1% myelocytes, 14% promyelocytes, and 47% blasts. The coagulation profile showed a decreased fibrinogen level of 115 mg/dl and increased fibrin split products exceeding 200 mg/dl, while other coagulation tests were normal. The initial bone marrow aspirate showed high hypercellularity with 90% infiltration by blast cells exhibiting a wide cytoplasm with marked promyelocyte-like granulation whereas Auer rods were absent ( Figure 1 ). Immunophenotyping showed 72% blasts (sideward scatter/ CD45, Figure 2a ) of markedly elevated granularity. Two subpopulations differed by CD45 expression: 47% had an expression level like granulocytes, 25% showed an elevated level (Figure 2b ). The blasts were positive for CD33, CD65, CD13, and HLA-DR (Figure 2c ). CD14 was expressed weakly, CD15, CD56 expression and cytoplasmic myeloperoxidase (cMPO) positivity were high (Figure 2d-f) . A subpopulation also expressed CD11b. In summary, the immunophenotype showed a myeloid pattern with several monocytoid features on large, markedly granular blasts. A lack of HLA-DR, typical for promyelocytic leukemia, was not found. After morphological analyses and immunophenotyping, the disease was clearly characterized as AML, but the question was whether it was a promyelocytic variant, monocytic, or myelomonocytic. Conventional cytogenetics and SKY were performed on bone marrow aspirates. Analysis of 20 metaphases by classical cytogenetics revealed two related female clones with 48 or 49 chromosomes and complex rearrangements in 16 metaphases ( Figure 3) . The karyotype after G-banding was as follows: 48,XX, þ marx2[1]/49,idem, þ X,i(7)(q10),der (22) [4] .
Fluorescence in situ hybridization (FISH) was used to validate the results of conventional cytogenetics and SKY, and to examine the material for PML-RARa fusion. Two FISH probes had been used. The Oncor translocation probe (AppligeneOncor, Heidelberg, Germany) contained a B45 kb unique sequence probe for PML and a B50 kb probe for RARa. These probes can detect PML-RARa and RARa-PML fusion genes. The Vysis dual color, dual fusion translocation probe (Vysis, Bergisch-Gladbach, Germany) contained an B500 kb unique sequence probe for PML and an B700 kb probe for RARa. Such very large probe can fail to detect small insertion. FISH with Oncor probes showed two signals for the PML gene on both chromosomes 15 as well as PML-RARa colocalization signals on the long arm of both chromosomes 17 in 97% of 114 analyzed metaphases ( Figure 4 ) and 98% of 150 interphase nuclei. In all, 2-3% showed no PML-RARa colocalization signals. FISH with the above-mentioned Vysis probes showed a normal signal pattern. FISH using wcpX, wcp1, wcp7, and wcp22 as well as 5p12 À and 5q31 À specific probes (AppligeneOncor, Heidelberg, Germany) confirmed aberrations detected by G-banding and SKY. Cohybridization of wcp15 and wcp17 probes (Appligene-Oncor, Heidelberg, Germany) showed a normal hybridization pattern. These results suggest that the insertion is very small and might concern the 3 0 part of PML, which is under-represented in the PML-RARa Vysis probes.
Multiplex reverse transcriptase polymerase chain reaction (RT-PCR) was performed as previously described with some modifications of specific primers to survey whether the PMLRARa or RARa-PML fusion had occurred or not. 6 The sequences of the oligonucleotides used for RT-PCR are given 5 0 -3 0 . For the first PCR: GAGAGAGTGAAGGCCCAGGTTCA, AGCTGCTG-GAGGCTGTGGACGCGC, and CCATAGTGGTAGCCTGAG- Correspondence GACT. For the second PCR: AGTGTACGCCTTCTCCATCAA, TGTGCTGCAGCGCATCCGCA, and GGCCAGCAACAG-CAGCTCCT. RNA isolated from a patient known to have the t(15;17)(q22;q21) was used as a positive control and sterile distilled water as a negative control. No PML-RARa or RARa-PML fusion transcripts had been detected.
Owing to the shortage and the quality of the material stored further experiments such as PML immunofluorescence, sequencing, long-range PCR or fiber FISH could not be performed.
The patient was classified as high-risk patient since the disease could not surely be classified as APL, and due to the complex rearranged karyotype with del(5q). She received a highly intensive therapy according to the APL protocol of the German AML Cooperative Group (AMLCG) with a first induction course of standard dose thioguanine -AraCdaunorubicin (TAD), a second course of high-dose AraC/mitoxantrone (HAM), and from day 4 through 100 of treatment oral ATRA. 7 After the initial TAD course, the bone marrow aspirate still showed persistent leukemia with hypercellularity and 70% blasts. Following the HAM course, a new bone marrow showed hypocellularity with less than 5% blasts and regeneration in the normal hematopoiesis, also confirmed by flow cytometry. Cytogenetic analysis revealed a normal female karyotype. No colocalization signals of the PML and RARa genes could be detected using FISH. For consolidation, the patient received a further TAD regimen, and after recovery of her blood counts, she was discharged from the hospital in good condition. Considering the complex cytogenetic abnormalities the patient underwent allogeneic stem cell transplantation from an HLA-identical family donor. On day þ 86 from transplant she had recovered well, but on day þ 150 a relapse was diagnosed. At this time, 20 G-banded metaphases were analyzed, and 12 metaphases showed a normal female karyotype. Eight metaphases revealed five related clones, showing additional abnormalities to those described at presentation. Surprisingly, no colocalization signal of the PML and RARa genes could be detected using the same FISH probes as in the initial two analyses. To exclude the possibility of false positive FISH at presentation, we repeated FISH with both samples. The sample taken at presentation remained positive for the ins(17;15) and the one taken at relapse remained negative. No fusion transcript of the PML and RARa genes could be detected by PCR.
The patient has been in a new remission after induction therapy, but she died 6 weeks after the diagnosis of relapse. Since another hospital took charge of the patient at relapse, it was not possible for us to find out the cause of the death.
Earlier studies reported that the t(15;17), diagnostic hallmark of APL, could be detected in all cases of APL. However, results of the European Working Party showed that a sizeable minority of APL lack the classic t(15;17). 5 Furthermore, the majority of these cases are still associated with formation of the PML-RARa fusion gene, as a result of insertions or rearrangements that are more complex. Such mechanisms typically lead to the formation of PML-RARa at its usual location on 15q and, less commonly, at the site of the reciprocal fusion gene on 17q, or at alternative chromosomal locations. 4 Insertions of PML material into both chromosomes 17q locations have, to the best of our knowledge, so far not been described elsewhere in AML cases. It might be suggested that either loss of the normal chromosome 17 and duplication of the der(17) chromosome or recombination between the two homologs after the insertion event have occurred. One possible mechanism concerning the first proposition could be a nondisjunction resulting in trisomy 17 with one normal and two derivative chromosomes 17. In a successive replication, the normal chromosome 17 then got lost.
Indeed, a mitotic recombination event leading to BCR-ABL fusion signals on both chromosomes 9 has been described in a Ph-negative case of chronic myeloid leukemia with submicroscopic ins(9;22). 8 Similar APL cases with apparently normal chromosomes 15 and 17 by conventional cytogenetic analysis, by FISH using wcp probes and by 24-multicolor karyotyping have been described. 5 The lack of fusion transcripts using RT-PCR can be explained either with the combination of variable positions of the PML breakpoints and insufficient variability of primers, 2 or with the insertion of PML material near to RARa, and not within it. The lack of a PML-RARa or RARa-PML colocalization signals at relapse suggests that the insertion of PML material in/or near to RARa detected at presentation was not the primary aberration. This could explain the difficulties to classify the cells morphologically and immunophenotypically. This case illustrates the importance of supplementing the longestablished methods such as morphology and classical cytogenetics with molecular approaches, such as FISH and PCR. It is important to confirm a cryptic insertion or translocation evidenced by FISH using a second molecular method such as PCR or RT-PCR in order to confirm the fusion signal corresponding to a functional fusion gene. All APL with cryptic insertions (15;17) or (17;15) evidenced by FISH with locusspecific probes express the PML-RARa transcript and thus respond to ATRA; only one case has been described with ins(17;15) expressing RARa-PML and not the reciprocal PML and RARa and does not respond to ATRA. 5 Identification of aberrations by molecular methods open the chance to let patients with cryptic rearrangements between PML and RARa also benefit from retinoids and novel agents such as arsenic trioxide (As 2 O 3 ). However, the therapeutic effect of ATRA itself in the patient described here cannot be definitely shown because of the active chemotherapy regimen given in addition due to the presence of a complex rearranged karyotype with del(5q).
